Welcome to STN International! Enter x:x

LOGINID:ssspta1200exs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available

```
NEWS 39   Jan 13  Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40   Jan 21  NUTRACEUT offering one free connect hour in February 2003
NEWS 41   Jan 21  PHARMAML offering one free connect hour in February 2003
NEWS 42   Jan 29  Simultaneous left and right truncation added to COMPENDEX,
                  ENERGY, INSPEC
NEWS 43   Feb 13  CANCERLIT is no longer being updated
NEWS 44   Feb 24  METADEX enhancements
NEWS 45   Feb 24  PCTGEN now available on STN
NEWS 46   Feb 24  TEMA now available on STN
NEWS 47   Feb 26  NTIS now allows simultaneous left and right truncation
NEWS 48   Feb 26  PCTFULL now contains images
NEWS 49   Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
              CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 10:11:11 ON 13 MAR 2003

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CAPLUS' ENTERED AT 10:11:23 ON 13 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 13 Mar 2003 VOL 138 ISS 11
FILE LAST UPDATED: 12 Mar 2003 (20030312/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 1,3-cyclic glycerophosphate
       7465882 1
       5712254 3
        258238 CYCLIC
          8095 GLYCEROPHOSPHATE
L1           2 1,3-CYCLIC GLYCEROPHOSPHATE
                 (1(W)3(W)CYCLIC(W)GLYCEROPHOSPHATE)

=> d l1 1-2 all

L1   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS
AN   2000:706969  CAPLUS
DN   133:261536
TI   Pharmaceutical compositions comprising cyclic glycerophosphates and
     analogs thereof for promoting neural cell differentiation
IN   Shinitzky, Meir
PA   Yeda Research and Development Co. Ltd., Israel
SO   PCT Int. Appl., 42 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  A61K031-00
CC   1-11 (Pharmacology)
     Section cross-reference(s): 29, 63
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
PI   WO 2000057865      A2   20001005       WO 2000-IL185     20000324
     WO 2000057865      A3   20010628
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     BR 2000009296      A    20011218       BR 2000-9296      20000324
     EP 1162959         A2   20011219       EP 2000-912877    20000324
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002540146      T2   20021126       JP 2000-607616    20000324
PRAI IL 1999-129178     A    19990325
     WO 2000-IL185      W    20000324
OS   MARPAT 133:261536
```

AB Cyclic glycerophosphates and analogs thereof (CGs) are shown to exert neural promoting activities in target cells. Such activities include promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain, prevention of nerve degeneration and nerve rescue. These activities of the CGs render them useful for treatment of various disorders including but not limited to mental disorders such as, for example, schizophrenia, dementia or disorders resulting in learning disabilities. In addn., these CGs may be used for the treatment of neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, conditions resulting from exposure to harmful environmental factors or resulting from a mech. injury. The CGs may also be used to treat an individual suffering from a primary neurodegenerative condition in order to prevent or reduce the appearance of secondary degeneration in addnl. nerves ("nerve rescue"). For example, neural outgrowth of PC12 cells was seen when cells were grown in the presence of nerve growth factor (50 ng/mL) or **1,3-cyclic glycerophosphate** (1 .mu.M), but not in the presence of linear .alpha.-glycerophosphate.

ST cyclic glycerophosphate neuronal differentiation mental disorder; antipsychotic schizophrenia cyclic glycerophosphate; Alzheimer disease parkinsonism cyclic glycerophosphate

IT Anti-Alzheimer's agents
Antiparkinsonian agents
Antipsychotics
Mental disorder
Nervous system agents
Schizophrenia
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Monoamines
Neurotrophic factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Nerve
(degeneration, prevention of; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Mental disorder
(dementia; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Nerve
(differentiation; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Learning
(disorder; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Nerve
(dopaminergic, degeneration of; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Cell differentiation

(inducers; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Nerve, disease
(injury, neuronal rescue after; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Cell differentiation
Cell differentiation
(neuronal; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Drug delivery systems
(oral; compns. comprising cyclic glycerophosphates for promoting neural
differentiation for therapeutic uses)
IT Drug delivery systems
(osmotic pumps; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Cell proliferation
(promotion of; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Drug delivery systems
(topical; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 298701-05-0P
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 711-07-9P 13507-10-3P 22227-09-4P 118897-32-8P 123406-35-9P 286020-33-5P 298701-06-1P 298701-08-3P 298701-09-4P 298701-78-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 51-61-6, Dopamine, biological studies 59-92-7, biological studies 102-32-9, DOPAC 306-08-1, Homovanillic acid
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 9001-86-9, Phospholipase C
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 57-55-6, 1,2-Propanediol, reactions 96-26-4, Dihydroxyacetone 504-63-2, 1,3-Propanediol 770-12-7, Phenyl phosphorodichloridate 819-83-0, Disodium .beta.-glycerophosphate 4799-67-1 14690-00-7, 2-Benzyloxy-1,3-propanediol 22002-87-5 26776-70-5, Dihydroxyacetone dimer
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. comprising cyclic glycerophosphates for promoting neural

differentiation for therapeutic uses)
IT 187976-16-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1993:534139 CAPLUS
DN 119:134139
TI Formation of **1,3-cyclic glycerophosphate** by the action of phospholipase C on phosphatidylglycerol
AU Shinitzky, Meir; Friedman, Peter; Haimovitz, Rachel
CS Dep. Membrane Res. Biophys., Weizmann Inst. Sci, Rehovot, 76100, Israel
SO Journal of Biological Chemistry (1993), 268(19), 14109-15
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English
CC 7-3 (Enzymes)
AB The action of phospholipase C (PLC) from Bacillus cereus on phosphatidylglycerol (PG), derived from egg yolk phosphatidylcholine (PC), was examd. in an ether-water mixt. The PLC cleavage of PG and PC followed a Michaelis-Menten kinetics with apparent Vmax values per 1 .mu.g enzyme of 0.26 and 0.91 .mu.mol.min-1 and Km values of 10 and 12 mM, resp. When the same enzymic reaction was carried out in minimally buffered aq. soln. of 1% Triton X-100, the decrease in pH with respect to phospholipid cleavage was as expected with PC but much less pronounced with PG. This could be accounted for by .alpha.-glycerophosphate, in the PLC hydrolysis of PG. Examn. of the chem. nature of the water-sol. product of PG by 31P NMR revealed a single band at 2.31 ppm, while the bands of .alpha.-glycerophosphate and .beta.-glycerophosphate appeared at 5.12 and 4.57 ppm, resp. Basic hydrolysis of the phospholipase cleavage product of PG (0.1 M NaOH for 1 min at 80 .degree.C) followed by neutralization shifted its 31P NMR band to 5.18 ppm, which practically coincided with that of .alpha.-glycerophosphate. Analogous expts. were carried out with PG labeled with 3H at the carbon 2 of the glycerol headgroup ([3H]PG). Autoradiog. of thin layer chromatog. (TLC) of the [3H]PG enzymic hydrolyzate displayed a single 3H-labeled compd., which could be converted to .alpha.-glycerophosphate by basic hydrolysis. These results strongly suggest that the phosphate headgroup of PG is cleaved off by PLC as **1,3-cyclic glycerophosphate**. A series of PLC expts. with phosphatidyldihydroxyacetone and phosphatidyl 1,3-propanediol as model substrates supported this assignment. Two-dimensional homonuclear 1H NMR correlated spectra as well as IR spectra carried out on the isolated sodium salt of this product could further confirm such a structure. The unique structure and chem. nature of **1,3-cyclic glycerophosphate** may bear a distinct physiol. function.
ST cyclic glycerophosphate formation phospholipase C phosphatidylglycerol
IT Phosphatidylglycerols
RL: RCT (Reactant); RACT (Reactant or reagent)

(cleavage of, by phospholipase C, cyclic glycerophosphate formation in)
IT Michaelis constant
(of phospholipase C, with phosphatidylglycerol)
IT Phosphatidylcholines, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with phospholipase C, kinetics of, phosphatidylglycerol in relation to)
IT 9001-86-9, Phospholipase C
RL: BIOL (Biological study)
(cyclic glycerophosphate formation by, of Bacillus cereus, in phosphatidylglycerol cleavage)
IT 42320-97-8
RL: FORM (Formation, nonpreparative)
(formation of, by phospholipase C cleavage of phosphatidylglycerol)
IT 149864-37-9
RL: FORM (Formation, nonpreparative)
(formation of, by phospholipase C cleavage of phosphatidylhydroxyacetone)
IT 13507-10-3
RL: FORM (Formation, nonpreparative)
(formation of, by phospholipase C cleavage of phosphatidylpropanediol)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.58	13.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 10:13:20 ON 13 MAR 2003